Sign in
Not yet recruitingNo phase

Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II

Key facts

Who runs it
Maastricht University Medical Center
Where
Netherlands4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
62 people, planned
Starts
1 Jan 2027
Expected to end
15 May 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Optimal cerebral perfusion pressure
Record updated
28 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult (>18 years old)
  • Severe TBI requiring ICP-directed therapy for at least 24 hrs on the assessment of the recruiting intensive care team and/or attending neurosurgeon
  • Start randomization within 24 hrs after ICU admission

Who cannot take part

  • Failure to get final written informed consent
  • Known pregnancy
  • Moribund at presentation (e.g. bilaterally absent pupillary responses)
  • Patients with a primary decompressive craniectomy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

After severe traumatic brain injury, adequate blood flow to the brain is essential for recovery. This depends on arterial blood pressure, yet intensive care units apply fixed targets to all patients - treating every brain and patient the same. This study aims to change that. With new technology, 'optimal' blood pressure can be determined for each individual brain and treatment can be tailored accordingly. This personalized approach to neurocritical care has never been tested in a randomized controlled study before. If effective in showing reduced brain damage biomarkers, it will fundamentally transform brain injury treatment and dramatically improve recovery outcomes for patients worldwide.

The 2 groups in the trial

  • CPPopt treatmentTreatment being tested

    The CPPopt treatment group will receive management according to the Brain Trauma Foundation (BTF) guidelines, except for the targeted cerebral perfusion pressure. Here, the calculated "optimal cerebral perfusion pressure (CPPopt)" will be targeted, with updated CPPopt targets every 4 hours. CPPopt treatment will be performed for a maximum of 5 days. If a patient still requires ICP treatment after 5 days, the standard, guideline-based treatment will be followed. CPPopt treatment can be shorter than 5 days, if ICP measurement is no longer required, if a patients wakes up, or if a patient dies.

    Treatment: Optimal cerebral perfusion pressure

  • Control groupNo study treatment, for comparison

    The intervention group will receive standard brain trauma management according to the Brain Trauma Foundation (BTF) guidelines, including the standard cerebral perfusion pressure target of 60-70 mmHg.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CPPopt Guided Therapy: Assessment of Target Effectiveness - II
Record updated
28 September 2026